A. Chalmers

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Gordon Cook, Cathy Williams, Julia Brown et al. · The Lancet Oncology · 2014 · 151 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +10

Prognostic Significance of Patient-Reported Outcomes in Cancer

Kathleen Kerrigan, Shiven B. Patel, Benjamin Haaland et al. · JCO Oncology Practice · 2020 · 55 citations · Full text

Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up

A. Chalmers, Shiven B. Patel, Kenneth M. Boucher et al. · Targeted Oncology · 2019 · 51 citations

Alk Therapy, Novel Therapy, Medicine +8

Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib

A. Chalmers, Laura Cannon, Wallace Akerley · The Oncologist · 2018 · 29 citations · Full text

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial

Dena Howard, Talha Munir, Lucy McParland et al. · Health Technology Assessment · 2017 · 17 citations · Full text